Results 221 to 230 of about 681,049 (265)
Some of the next articles are maybe not open access.
Study of Tyrosine Kinases and Protein Tyrosine Phosphorylation
2004In recent years, our increased understanding of the complex signal transduction mechanisms that regulate cellular function has fueled huge advances in all aspects of biomedical science and cell biology. Platelet and megakaryocyte function is no exception to this. In the last 10 yr our understanding of the receptor biochemistry and the systems that they
openaire +2 more sources
Oxidation of Tyrosine Diketopiperazine to DOPA Diketopiperazine with Tyrosine Hydroxylase
Journal of Natural Products, 2004The diketopiperazine of DOPA was synthesized in high yield from the diketopiperazine of tyrosine using PC12 cell lysate, which expresses high levels of tyrosine hydroxylase. This represents the first use of this enzyme to prepare DOPA-containing peptides.
Maysoon B, Saleh, Russell G, Kerr
openaire +2 more sources
Negative Regulation of a Protein Tyrosine Phosphatase by Tyrosine Phosphorylation
Journal of the American Chemical Society, 2006The low molecular weight protein tyrosine phosphatase (LMW-PTP) is a ubiquitously expressed enzyme with several proposed roles in cell signaling. Previously, two tyrosine phosphorylation modifications of LMW-PTP at sites Tyr-131 and Tyr-132 in response to growth factor stimulation have been mapped and suggested to stimulate LMW-PTP phosphatase activity.
Dirk, Schwarzer +3 more
openaire +2 more sources
Targeted tyrosine iodination in a multi‐tyrosine vasopressin analog
Journal of Peptide Science, 2007AbstractIodination of the conserved 2‐tyrosine (Tyr2) residue in the pressin and tocin rings of arginine‐ or lysine‐vasopressin (AVP or LVP), and oxytocin, respectively, impairs binding to their respective receptors. Synthetic antagonists that have their Tyr2 either replaced by another amino acid or irreversibly blocked by an O‐methyl or O‐ethyl ether,
Jacques A, Durr +3 more
openaire +2 more sources
Tyrosine transaminase: Inactivation by tyrosine metabolic end products
Biochimica et Biophysica Acta (BBA) - Enzymology, 1970Abstract The tyrosine metabolites, p- hydroxyphenylpyruvate , homogentisate, and fumarylacetoacetate were examined as inhibitors and inactivators of purified rat liver tyrosine α-ketoglutarate transaminase. Of these, homogentisate proved to be a very powerful inactivator when the enzyme was preincubated with it. This effect was blocked by prior
M, Civen, C, Wilson, C B, Brown
openaire +2 more sources
A Quantitative Assay for Tyrosine Sulfation and Tyrosine Phosphorylation in Peptides
Biological Chemistry Hoppe-Seyler, 1990A method was developed to measure sulfation and phosphorylation of tyrosine in proteins after alkaline hydrolysis, ion-exchange chromatography, reaction with [3H]dinitrofluorobenzene and subsequent thin-layer chromatography. The method allows the detection of 10-20 pmol of modified tyrosine and was applied to determine the content of tyrosine-phosphate
H, Blode, T, Heinrich, H, Diringer
openaire +2 more sources
Tyrosine-dependent increase of tyrosine hydroxylase in neuroblastoma cells
Nature, 1974TYROSINE hydroxylase (tyrosine-3-monooxygenase), presumably the rate-limiting enzyme in the biosynthesis of the adrenergic transmitters dopamine and noradrenaline1,2, catalyses the hydroxylation of both phenylalanine and tyrosine3,4. This property has been exploited for the selection of adrenergic-like mouse neuroblastoma cells5, which have high ...
Lloyd, T, Breakefield, X O
openaire +2 more sources
Current Opinion in Oncology, 1997
This review covers the literature on significant studies of small molecule inhibitors of the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), Flk-1, and src family tyrosine kinases from 1996 through mid-1997. During this period, there has been substantial progress in the
W D, Klohs, D W, Fry, A J, Kraker
openaire +2 more sources
This review covers the literature on significant studies of small molecule inhibitors of the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), Flk-1, and src family tyrosine kinases from 1996 through mid-1997. During this period, there has been substantial progress in the
W D, Klohs, D W, Fry, A J, Kraker
openaire +2 more sources